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Huntington’s disease (HD) is a progressive and autosomal dominant neurodegeneration
caused by CAG expansion in the huntingtin gene (HTT ), but the pathophysiological
mechanism of mutant HTT (mHTT) remains unclear. To study HD using systems biological
methodologies on all published data, we undertook the first comprehensive curation of
two key PubMed HD datasets: perturbation genes that impact mHTT-driven endpoints
and therefore are putatively linked causally to pathogenic mechanisms, and the protein
interactome of HTT that reflects its biology. We perused PubMed articles containing
co-citation of gene IDs and MeSH terms of interest to generate mechanistic gene sets for
iterative enrichment analyses and rank ordering. The HD Perturbation database of 1,218
genes highly overlaps the HTT Interactome of 1,619 genes, suggesting links between
normal HTT biology and mHTT pathology. These two HD datasets are enriched for
protein networks of key genes underlying two mechanisms not previously implicated in
HD nor in each other: exosome synaptic functions and homeostatic synaptic plasticity.
Moreover, proteins, possibly including HTT, and miRNA detected in exosomes from a
wide variety of sources also highly overlap the HD datasets, suggesting both mechanistic
and biomarker links. Finally, the HTT Interactome highly intersects protein networks of
pathogenic genes underlying Parkinson’s, Alzheimer’s and eight non-HD polyglutamine
diseases, ALS, and spinal muscular atrophy. These protein networks in turn highly overlap
the exosome and homeostatic synaptic plasticity gene sets. Thus, we hypothesize
that HTT and other neurodegeneration pathogenic genes form a large interlocking
protein network involved in exosome and homeostatic synaptic functions, particularly
where the two mechanisms intersect. Mutant pathogenic proteins cause dysfunctions
at distinct points in this network, each altering the two mechanisms in specific fashion
that contributes to distinct disease pathologies, depending on the gene mutation and
the cellular and biological context. This protein network is rich with drug targets, and
exosomes may provide disease biomarkers, thus enabling drug discovery. All the curated
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datasets are made available for other investigators. Elucidating the roles of pathogenic
neurodegeneration genes in exosome and homeostatic synaptic functions may provide
a unifying framework for the age-dependent, progressive and tissue selective nature of
multiple neurodegenerative diseases.
Keywords: extracellular vesicles, synaptic scaling, Alzheimer’s disease (AD), polyglutamine, systems biology,
spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS), synaptic plasticity
INTRODUCTION
Huntington’s disease (HD) is a monogenic, dominantly inherited
neurological disorder caused by a CAG expansion in the
huntingtin gene (HTT), and is one of nine neurodegenerative
diseases caused by polyglutamine (polyQ) expansion. HTT is
a large protein of 3,144 amino acids, and when the glutamine
encoded in exon 1 exceeds 35, it causes a slow-onset, progressive
neurodegeneration, with an age of onset that is inversely Q
length-dependent (Andrew et al., 1993; Duyao et al., 1993;
The Huntington’s Disease Collaborative Research Group, 1993;
Langbehn et al., 2010). Although HTT is ubiquitously expressed,
HD largely manifests in motor, cognitive, and other neurological
symptoms (Reiner et al., 2011). The N terminal fragments of
mutant HTT (mHTT) is prone to misfolding and aggregation
(Scherzinger et al., 1997; Poirier et al., 2002; Thakur et al., 2009),
a feature shared with pathogenic proteins implicated in other
neurodegenerative diseases. How mHTT ultimately causes HD
still isn’t clear, but wild type (WT) HTT has been implicated in a
wide variety of biological functions on the cellular level, many
of which are impacted by the mutation (reviewed in Imarisio
et al., 2008; Ross and Tabrizi, 2011; Labbadia and Morimoto,
2013). Aside from tetrabenazine for symptomatic relief, there
is currently no effective disease modifying treatment available,
although several are under development (Wild and Tabrizi, 2014;
Dayalu and Albin, 2015).
Numerous transgenic and knock-in rodent HD models and
other experimental platforms utilize mHTT to drive a variety
of endpoints presumed to be relevant for disease pathology,
such as behavioral phenotypes in whole organisms, cell toxicity,
and protein aggregation. However, these are often driven by
overexpression of high Q length HTT fragments. In principle,
genetic perturbations or small molecules that impact these
endpoints are causal for mHTT pathophysiology. However,
uncertainties regarding the disease relevance of the HD platforms
and mHTT-driven endpoints, and the sheer volume of these
perturbation data that make systematic analyses difficult, have
stymied progress in elucidating disease mechanisms. Small
molecule screening in HD platforms has also not progressed to
drug development, leading to a search for alternate and novel
assays (reviewed in Bard et al., 2014).
Given the challenges, a systematic analysis of all existing
HD perturbation data from comprehensive curation of the
HD literature would be desirable if only to settle whether
they hold value. We undertook such an effort over several
years, creating a comprehensive HD perturbation database
(PerturbDB) from a systematic survey of the HD literature of
∼12,500 PubMed articles (current to May 2014) to identify the
456 containing perturbation data that meet predefined criteria,
from which a total of 1,218 genes were curated into PerturbDB.
The database had been made freely available online during
its creation, and an analysis of an early version containing
694 genes had been published (Kalathur et al., 2012). The
authors highlighted several biological areas from enrichment
analysis with GO terms and KEGG Pathways, but did not
analyze in detail the heterogeneous data types or uncover
novel pathophysiological mechanisms. We analyzed an updated
and much larger PerturbDB, complemented by a curated set
of proteins associated with HTT (HTT Interactome, 1,619
in total), with a database-enabled methodology of efficient
surveying of PubMed for mechanisms linked to the HD datasets,
then building specific mechanistic gene sets for enrichment
analyses followed by their rank-ordering, and finally formulating
testable hypotheses. We hypothesize that exosome biology and
homeostatic synaptic plasticity (HmSP, used here instead of HSP
to avoid confusion with heat shock protein), not previously
linked to each other or to HD, are functionally linked together
and are altered in HD. Moreover, the HTT interactome highly
intersects protein networks of pathogenic genes underlying
Parkinson’s Disease (PD), other polyglutamine (PolyQ) diseases,
Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS),
and spinal muscular atrophy (SMA). All the protein networks
of these disease genes also link to exosome biology and HmSP,
suggesting that an overlapping protein network connecting these
pathogenic proteins gives rise to distinct disease pathologies
depending on disease and biological context. All of the curated
databases utilized are provided in this publication to enable
the scientific community to undertake further analysis and
experimental verification.
METHODS
PerturbDB
We systematically and comprehensively curated the PubMed HD
literature (query terms: Huntington’s, Huntington, huntingtin)
through May 2014 (∼12,500 PMIDs) to select articles that
met the predefined “perturbation” criterion for PerturbDB:
that a gene is perturbed, by either genetic or pharmacological
means, in an experimental platform that produces one or
more mHTT-dependent endpoint. Putatively, genes whose
perturbation impacted mHTT-driven endpoints are causally
linked to mHTT pathophysiology. Human genes in which SNPs
are reported to modify age of onset of HD are also included. As
discussed previously (Kalathur et al., 2012), these criteria were
originally part of a Target Validation scoring system developed
by the CHDI Foundation. Four thousand and fifty-six PubMed
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articles met this criterion and a total of 1,266 unique genes
were curated into PerturbDB (genes found to have no impact
were included but filtered out for this analysis). The specific
curation attributes, such as experimental platform, mHTT size,
nature of perturbation, and endpoints, are shown in Table S1
in Supplementary Datasheet 4. Genes tested in different species
were all mapped to orthologous human Entrez gene IDs, and
where there was no match (certain mouse immune function
genes, and a small number of yeast, fly, and worm genes) they
were excluded from the database, as they are not likely to be
relevant for human biology. Certain fly and worm genes each
mapped to multiple human orthologs that are closely related, and
these were all included to represent the original single gene. For
small molecule perturbations the gene ID of the most likely drug
target was used. The entire PerturbDB table, with 1,839 unique
entries and 212 data columns, is provided in Supplementary
Datasheet 1. Excluding genes that had no effect, a total of 1,218
genes impacted mHtt-dependent outcomes in at least one HD
experimental platform. These genes, and subsets representing
the six major experimental platforms within PerturbDB, were
analyzed as described in Results and Discussion. We did not
analyze other potentially informative avenues, for example with
an endpoint of HTT protein level, but leave it to other interested
investigators to utilize the dataset. In addition, the PerturbDB
genes, tagged with their experimental summaries, are included
in a Master Data Table containing all other gene sets used for this
publication (Supplementary Datasheet 2).
HTT Interactome
We curated five major proteomics studies for proteins
associated with WT or mHTT using yeast two-hybrid (Y2H) or
immunoprecipitation-pull-down from cells and brain tissues.
The first study used Y2H (Goehler et al., 2004), followed by one
that also used Y2H but also Tagged Affinity Purification-Mass
Spectrometry on cells and brain extracts (Kaltenbach et al.,
2007). A follow-on study extending the ∼100 Y2H interactors
to 1,207 secondary interactors (Tourette et al., 2014) was
published after our primary analysis was completed and is not
included. However, 28% of this set is already in our curated HTT
Interactome, having come from other sources. Interactomes
from different brain regions of BACHD mouse at different ages
(Shirasaki et al., 2012), from cytoplasm and membrane-bound
brain fractions of the CAG140 mouse (Culver et al., 2012),
and differential interactors between normal HTT and mHTT
in striatal cell lines (Ratovitski et al., 2012) were curated.
Combining these interactome data with miscellaneous published
HTT protein-protein interactors (PPI) curated in Ingenuity
IPA (QIAGEN, Redwood City, www.qiagen.com/ingenuity) and
the HIPPIE database (http://cbdm.mdc-berlin.de/tools/hippie/
information.php; HIPPIE includes data fromGoehler et al., 2004)
result in 1,619 unique genes whose protein products are part of a
combined HTT Interactome. This dataset as a whole (and the five
constituent subsets) is included in Supplementary Datasheet 2.
Gene Sets
Genes implicated in different biological functions were curated
from various sources and are integrated in the master data table
in Supplementary Datasheet 2. A set of 3,549 genes involved in
various synaptic functions was curated from several publications
and databases (Ashburner et al., 2000; Collins et al., 2006; Zhang
et al., 2007; Abul-Husn et al., 2009) and is named SynapseDB.
A subset of 1,097 genes implicated in postsynaptic neuronal
functions (Collins et al., 2006) is also analyzed on its own for
comparison with the larger SynapseDB.
Genes implicated in exosome functions, primarily its release
from nerve terminals in the Drosophila neuromuscular junction
(NMJ; Ataman et al., 2008; Korkut et al., 2009, 2013; Fainzilber
et al., 2011; Koles et al., 2012; Kerr et al., 2014), but also the
multi-vesicular bodies and 14-3-3 proteins (Fraser et al., 2013)
in mammalian cells, were curated from PubMed. PPI of each
of these exosome functional genes were obtained from HIPPIE
and from Ingenuity IPA. These two databases highly overlap each
other as both are curated from PubMed, and it should be noted
we did not impose any other selection criteria on the curation, as
all results from these two sources that can be mapped to human
Entrez gene IDs are included.
Proteins identified in high throughput studies of exosomes or
extracellular vesicles from cells, fluids and tissues were curated
from online databases (Vesiclepedia: http://microvesicles.org/;
data downloaded January 2014), as is a set of 755 miRNA (the
latter shown in Supplementary Datasheet 3). A list of the top
200 proteins most often found in high throughput studies of
exosome from EVpedia (http://student4.postech.ac.kr/evpedia2_
xe/xe/), and a set of proteins detected in exosomes from human
CSF (Chiasserini et al., 2014) are also included. The Exosome
Protein DB therefore contains a total of 4,019 proteins. Genes
required for presynaptic HmSP in the DrosophilaNMJ (reviewed
in Frank, 2014), and postsynaptic and other forms of HmSP
in mammalian neuronal cultures were curated from PubMed.
PPI of these genes were then constructed from HIPPIE and
Ingenuity IPA.
It should also be noted that Supplementary Datasheet 2
includes other gene sets of interest to the field, including
PPIs of those involved in proteolysis or degradation of HTT
and mHTT (e.g., the NUB1 and CUL genes from a screen
based on mHTT protein levels; Lu et al., 2013), and for
autophagy, lysosome and ubiquitome functions, different aspects
of mitochondrial function and biology, and several transcription
factors relevant to HD (e.g., p53, HDACs, CBP, NRF2, and
PGC-1α).
Protein interactors of genes implicated in neurodegenerative
diseases, including PD, polyglutamine diseases (but excluding
HD), ALS, SMA, and AD were also constructed in HIPPIE
and IPA. The PD set contains five genes (LRRK2, PARK2,
PARK7, PINK1, SNCA) for a PPI total of 763. The AD set
consists of APP, PSEN1, PSEN2, and MAPT (tau), of which
APP contributes the bulk of the PPI of 2,354 (∼90% of the
set). The PolyQ set contains genes for seven polyglutamine
diseases (SCA1-ATXN1; SCA2-ATXN2; SCA3-ATXN3; SCA6-
CACNA1A; SCA7-ATXN7; SCA17-TBP; DRPLA-ATN1; SBMA-
AR; all as disease-gene symbol pairs) for a total of 1,139
PPI. The ALS set consists of SOD1, TARDBP, and FUS, with
328 total. C9orf72 was not included because only a handful
of PPIs are known. The SMA set contains 241 PPI for
SMN1/2. All of these gene sets are found in Supplementary
Datasheet 2.
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Other Data Sources
Gene IDs linked to PubMed articles were downloaded using
the gene2pubmed tool ftp://ftp.ncbi.nih.gov/gene/DATA/
gene2pubmed.gz; and other sources include publically available
GO, KEGG, and REACTOME.
Building and Analyzing Integrated
Databases
Multiple Access databases were customized for the type of
analyses at hand during the workflow depicted in Figure 1.
For example, PerturbDB has an Access Form displaying for
each gene the experimental platform and attributes such as
perturbation and outcome measures (Figure S1), making it easy
to query for different combinations of attributes such as those
found in two or more platforms (see Supplementary Material
Section 1.2 in Supplementary Datasheet 4). After analyses of
the PerturbDB data, the HTT Interactome was incorporated
to enable analyses of the two datasets, with additional fields
added for the HTT Interactome in the Access Form (not shown).
To query PubMed articles that co-cite gene IDs and MeSH
terms of interest, additional databases incorporated the HD
gene IDs, the selected MeSH terms and the number of co-
citation articles, with link-outs to the abstracts for the MeSH
headings (Figure S2). This allows for efficient surveying of
multiple corners of PubMed containing articles co-citing the
HD genes (and other gene sets) with particular MeSH headings.
The iterative selection of new MeSH terms using this approach
then leads to potentially interesting HD mechanisms for which
mechanistic gene sets can be built for enrichment analyses and
rank-ordering.
Statistical Analysis
Statistical significance of gene set overlaps was tested using
Fisher’s exact test. For each round of testing we used as reference
set a large collection of ∼2,000 gene sets that include all
genes from public sources (GO, KEGG etc.) and all custom-
curated gene sets, representing a wide diversity of biological
functions. We used Benjamini-Hochberg FDR estimates, derived
independently for each query set from the p-values of its overlaps
with all reference sets, to correct for the large number of statistical
tests. Since all of our query gene sets were compiled from
the literature, we cannot a priori exclude the possibility that
some of the query and reference gene sets are not independent;
hence, reported p-values should be treated as descriptive rather
than inferential. We rank-order the results and generally only
examine the most highly ranked top gene sets for mechanisms
and biology of interest. To make our results more reader-
friendly, we report enrichment significance as −log10 FDR,
denoted −log FDR. We use an arbitrary minimum cutoff of
−log FDR value of 10, because in almost all cases the top
ranking gene sets show values much higher than 10, often
into the 100s. Thus, we rely more on the relative rank order
and degree of overlap between datasets than the absolute
values.
Area proportional Venn diagrams were plotted using the
eulerAPE program using ellipses (Micallef and Rodgers, 2014).
FIGURE 1 | Flow chart of the database-enabled methodology to link
and query data of interest (HD) with literature and other data, followed
by enrichment analyses and hypotheses formulation. The flow chart
depicts the multiple streams of structured data that are integrated into the
federated HD database (HD_DB) to enable efficient iterative querying of
PubMed and enrichment analyses rank order the top mechanisms and
formulation of testable hypotheses.
RESULTS AND DISCUSSION
Overview of the Database-Enabled
Methodology
Our overall strategy on analyzing large datasets is to first
systematically curate them into databases for initial analysis to
determine their usefulness for further work, then to integrate
them into databases with iteratively selected PubMed literature
to produce mechanistic gene sets for enrichment analyses and
rank ordering, as outlined in Figure 1 and detailed in Methods
Section Building and Analyzing Integrated Databases. Applying
this workflow, we analyzed PerturbDB (genes putatively linked
to mHTT pathophysiology) and the HTT Interactome (proteins
in complex with HTT and presumed to be involved in HTT
biology), and concluded that they qualified as foundational
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HD datasets (summarized in Section Overview of the HD
Datasets and detailed in Supplementary Material Section 1
in Supplementary Datasheet 4). We then curated PubMed
articles co-citing the HD gene IDs and MeSH terms of interest
and manually surveyed them for potential HD mechanisms.
Done in the far more efficient database format described in
Methods Section Building and Analyzing Integrated Databases,
we iteratively surveyed the literature with progressively focused
MeSH terms to custom-build specific mechanistic gene sets
that were incorporated into an ever-growing gene set collection
for enrichment analysis. Rank ordering of the top mechanisms
then lead to in-depth study and hypotheses formulation, as
discussed below. This methodology is particularly useful for large
datasets as it facilitates surveying large and often-unfamiliar
swaths of PubMed, combining the efficiency of automated
database federation with insights from manual perusal of the
integrated literature. Future implementation of this methodology
could include natural language processing tools to improve the
efficiency and accuracy of literature curation associated with
identifiers for genes or chemicals. Deploying this methodology,
we settled on a final database (master data table in Supplementary
Datasheet 2) containing gene sets of exosome biology and HmSP
as the top ranking mechanisms from enrichment analyses of
datasets from HD and other neurodegenerative diseases.
Overview of the HD Datasets
The Two HD Datasets Highly Intersect Each Other
and Are Worthy of Further Analysis
The detailed analysis of the two comprehensively curated HD
datasets, PerturbDB (1,218 genes) and the HTT Interactome
(1,619 genes), is presented in Supplementary Material (Section
1 in Supplementary Datasheet 4), and we only summarize
the main findings here. The validity of the causal relationship
to mHTT pathology of the genes in PerturbDB, with their
disparate cellular context and mHTT-driven endpoints, has
long been debated. However, the major PerturbDB experimental
platforms, in particular those of Drosophila in vivo phenotypes,
mammalian mHTT aggregation, and cell culture toxicity,
highly overlap each other despite their very different biological
context (Supplementary Section 1.2; Table S2A in Supplementary
Datasheet 4). Thus, there are likely common mechanisms
mediating mHTT-induced dysfunctions despite the disparate
cellular context and endpoints. Moreover, PerturbDB highly
overlaps the HTT Interactome, at ∼30% between the two (−log
FDR ∼131), and again more so for the three major experimental
platforms (Tables S2A,B; Figures S3A,B in Supplementary
Datasheet 4). As the HTT Interactome by and large represents
normal functions of HTT (only a relatively small number of
HTT interactors are specific for either mHTT or HTT), the high
number of HTT interactors that can perturb mHTT endpoints
suggests that mHTT can both drive gain-of-function pathologies
and disrupt normal biology of HTT. The comprehensive nature
of the HTT Interactome and its origin from multiple sources
also make it more likely to fill biological gaps not studied in the
more hypotheses-driven PerturbDB datasets. Thus, we conclude
that these two HD datasets are suitable as foundational data with
which to apply our database-enabled methodology and workflow
to formulate hypotheses on mHTT pathogenic mechanisms, as
shown in Figure 1.
Exosome Biology and HD
Exosomes Provide Novel Intercellular
Communication System for Synaptic Functions
As described in Supplementary Material Section 2 in
Supplementary Datasheet 4, we first curated a large set of
genes possessing neuronal and synaptic functions (SynapseDB)
and found highly significant enrichment of the HD datasets
(Table S3, Figure S4 in Supplementary Datasheet 4), not
surprising for a neurodegenerative disease. We then found
that a small set of genes critical for synaptic vesicle functions
are found in the HD datasets (Table S4 in Supplementary
Datasheet 4). While examining these genes, we encountered
an interesting set of studies on exosomes (or more broadly,
extracellular vesicle or EV) in neuronal functions in which many
of these synaptic genes are implicated (Ataman et al., 2008;
Korkut et al., 2009, 2013; Fainzilber et al., 2011; Koles et al.,
2012; Kerr et al., 2014). Exosomes are 50–100 nm extracellular
vesicles released and taken up by all cells both for intercellular
communication and for disposal of cellular material (reviewed
in Pant et al., 2012; Kalani et al., 2014). Exosome biology is
only beginning to be studied intensively in the nervous system,
both as a novel means of intercellular communication and as
a pathogenic mechanism in neurodegeneration (Chivet et al.,
2013; Costanzo and Zurzolo, 2013; Schneider and Simons,
2013; Rajendran et al., 2014; Tsilioni et al., 2014; Coleman and
Hill, 2015). The “transmissibility” of misfolded and aggregated
forms of pathogenic proteins for multiple neurodegenerative
disorders, as has been shown for prions, together with possible
involvement of exosome-like secreted vesicles, have generated
a great deal of interest. Thus, the detection of α-synuclein,
LRRK2, Aβ and tau, prions, SOD1, and TDP-43 in exosomes
suggests one means by which these pathogenic proteins could be
propagated in Parkinson’s (PD), Alzheimer’s (AD), Creutzfeldt–
Jakob disease, and ALS. On the other hand, exosomes may
also ameliorate the disruption of synaptic plasticity by Aβ
via sequestration on surface proteins (An et al., 2013). Thus
far no direct link between exosome and mHTT has been
reported, although transfer of polyglutamine aggregates between
neurons via “tunneling nanotubes” (Costanzo et al., 2013),
and transneuronal propagation of mHTT that depends on the
vesicular fusion machinery (Pecho-Vrieseling et al., 2014), and
transfer between neurons and glia (Pearce et al., 2015) have
been reported. Moreover, forward genetics studies in Drosophila
larval NMJ showed that wnt signaling, in a bidirectional
manner, mediates synaptic structural changes and a particular
form of plasticity in response to spaced intensive interval
stimulation (Ataman et al., 2008; Korkut et al., 2009, 2013;
Fainzilber et al., 2011; Koles et al., 2012; Kerr et al., 2014).
This NMJ synaptic plasticity requires coordination between
presynaptic motor neuron and postsynaptic muscle cell in
both anterograde and retrograde directions, whereby alteration
in presynaptic neurotransmitter release is tightly coupled
to the number of postsynaptic neurotransmitter receptors.
This coordination is in turn mediated by release of exosomes
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bearing wnt binding partners from the motor neuron terminal
and their uptake by the postsynaptic muscle fiber. Thus, in
addition to the well-characterized inter-neuronal and synaptic
communication systems, exosomes provide yet another level of
control on a form of Drosophila NMJ synaptic plasticity. The
importance of exosomes in well-characterized forms of synaptic
plasticity and whether they contribute to synaptic deficits in
neurodegeneration, however, is unclear.
Genes Required for Exosome Functions and Their
Protein-Protein Networks Are Enriched in the HD
Datasets
The Drosophila studies identified eight genes critical for the
release and two genes for the uptake of exosomes at the NMJ.
We mapped these 10 genes to 13 human orthologs, adding
family members for ADP-ribosylation factor, vacuolar proton
pump ATPases, and dynamin due to the presence of these
related mammalian orthologs in HD datasets. These genes are
shown in Table 1, together with 14-3-3 proteins and the ESCRT
complexes involved in the life cycle of exosomes (Colombo
et al., 2013; Fraser et al., 2013), and their relationships to
the HD datasets. Strikingly, all the mammalian orthologs of
the Drosophila genes are also found in PerturbDB and/or the
HTT Interactome (Table 1, rows 1–13). These are synaptic
vesicle fusion and endocytosis genes (syntaxin 1A, RAB11,
dynamin, and clathrin); vacuolar proton pump ATPases for
organelle acidification; ADP-ribosylation factor; Myosin V; 14-
3-3 proteins required for the release of exosomes containing
LRRK2, a pathogenic PD gene (Fraser et al., 2013); and the
ESCRT complexes required for endosomal trafficking through
the multi-vesicular bodies (MVBs). Indeed, ALL 27 genes for
exosome function in the neuronal context thus far have also
been independently implicated as modifiers of mHTT-driven
endpoints and/or as part of the HTT Interactome, with 21
out of the 27 in the former, 19 in the latter, and 13 found
in both (Table 1). This strong concordance indicates a close
relationship between exosome and HTT biology and mHTT
pathology. Interestingly, the overlap with PerturbDB is almost
exclusively in Drosophila in vivo phenotypes and the protein
aggregation platforms (Table 1), two of three that stand out as
most highly intersecting with other PerturbDB platforms and
with the HTT Interactome. The 11 Drosophila genes are in
synaptic vesicle biology or are members of the 14-3-3 and ESCRT
families, and their concordance in larval NMJ exosome function
and pan-neuronal mHTT phenotypes in adult brain implicates
exosome biology in the complex behavioral phenotypes of
mHTT. The overlap with the aggregation platforms, on the other
hand, implicates protein metabolism and processing in exosome
biology in the context of mHTT, perhaps due to the dual roles
of exosome in protein cargo delivery/disposal and in intercellular
communication.
To perform robust enrichment analyses and to widen the
gene sets to test for specific mechanisms involving exosomes, we
curated and combined PPIs for each of the mammalian exosome
functional genes to produce a protein network important for
exosome release and uptake. This Exosome Synaptic PPI set of
892 genes would be analogous to the HTT Interactome and
therefore suitable for enrichment analysis (see Supplementary
Datasheet 2 for the gene sets). The 14-3-3 genes and ESCRT
complex members were not included as they form very large
protein interaction networks on their own and are probably best
analyzed separately (PPIs of these two families are nevertheless
included in Supplementary Datasheet 2). We summarize here
the main findings for the two HD datasets, while details are
found in Supplementary Material (Section 3 in Supplementary
Datasheet S4).
The Exosome Synaptic PPI is highly enriched in the HTT
Interactome and PerturbDB, overlapping∼18% of each of them,
and even more so the HD Common set of genes at 33% with
high –log FDR values (Table 2). Thus, genes found in both HD
datasets shows a higher relative percentage of overlap compared
to either HD dataset alone. That the protein network of genes
critical for exosome synaptic functions highly intersects the
HTT Interactome further supports a link between exosome
and HTT biology. The overlap with PerturbDB (the Drosophila
in vivo phenotypes and mammalian mHTT aggregation are
again the two highest overlapping, Table S5 in Supplementary
Datasheet 4) in turn suggests that certain mHTT dysfunctions
may involve exosome biology. Thus, these results strengthen
and extend the hypothesis that synaptic and neuronal functions
of exosomes are linked to HTT and mHTT. This hypothesis
can be experimentally verified in the Drosophila NMJ and then
extended tomammalian experimental platforms, and followed by
elucidating therapeutic opportunities in exosome function linked
to mHTT pathophysiology.
Proteins and miRNA Detected in Exosomes are
Highly Enriched in HD Datasets
The contents of exosomes or extracellular vesicles have been
profiled in a variety of cells and tissues, and these data are
aggregated in public databases (see SectionMethods for sources).
We curated a set of proteins (Exosome ProteinDB, with 4,019
genes) and miRNA (755 in total) detected in exosomes from
a variety of tissues and cells for enrichment analysis. Almost
all of the tissues and cells reported are non-neuronal, with
the exception of a set of 739 proteins detected in human
CSF exosomes (Chiasserini et al., 2014). A detailed analysis of
the intersection of this dataset with the HD data subsets is
presented in SupplementaryMaterial Section 3 in Supplementary
Datasheet S4.
Despite the relative paucity of data from brain and neuronal
tissues, the Exosome ProteinDB still highly intersects the HTT
Interactome (51% of the latter, −log FDR ∼228; Table 2),
PerturbDB (42%, −log FDR ∼92) and in particular the HD
Common set (62%, −log FDR ∼79). Half of the Exosome
Synaptic PPI set (442 genes) is found in the Exosome ProteinDB,
and both highly overlap the HD datasets (see Venn diagram
in Figure 2). Indeed, only 35% of the Exosome Synaptic PPI
set is not intersected. Thus, many HTT associated proteins
may be either exosomal components or signaling molecules,
and contribute to mHTT pathophysiology by altering exosome
functions. Also noteworthy is that HTT itself is detected as
protein in exosomes or extracellular vesicles from human B cells
(Meckes et al., 2013), thymic tissue (Skogberg et al., 2013) and
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TABLE 1 | Overlap of Exosome Functional Gene Set with PerturbDB and HTT Interactome.
Exosome function Dme gene Gene symbol Gene name PerturbDB HTT Interactome
1 Release Arf79f ARF1|3 ADP-ribosylation factor class I Yes
2 ARF4|5 ADP-ribosylation factor class II Aggreg
3 Release Vha68-2 ATP6V1A ATPase, H+ transporting Aggreg Yes
4 Release Vha55 ATP6V1B2 ATPase, H+ transporting Yes
5 ATP6V1B1 ATPase, H+ transporting Aggreg
6 Release Vha26 ATP6V1E1 ATPase, H+ transporting Aggreg Yes
7 Release VhaSFD ATP6V1H ATPase, H+ transporting Aggreg Yes
8 Release Myo5 MYO5A|B Myosin V Yes
9 Release Rab11 RAB11A|B Rab 11 HD Fly; Aggreg Yes
10 Release Syx1a STX1A Syntaxin 1A HD Fly Yes
11 Uptake Chc CLTC Clathrin, heavy chain HD Fly Yes
12 Uptake Shi DNM1 Dynamin 1 HD Fly Yes
13 DNM2 Dynamin 2 Aggreg; Cell Tox Yes
14 Release YWHAB 14-3-3 family HD Fly Yes
15 YWHAE 14-3-3 family HD Fly; Aggreg Yes
16 YWHAZ 14-3-3 family HD Fly; Aggreg Yes
17 YWHAG 14-3-3 family HD Fly Yes
18 YWHAH 14-3-3 family Yes
19 YWHAQ 14-3-3 family Yes
20 MVBs VPS28 ESCRT-I Complex HD Fly
21 VPS25 ESCRT-II Complex HD Fly
22 CHMP3 ESCRT-III Complex Aggreg
23 CHMP4A ESCRT-III Complex Aggreg
24 CHMP4B ESCRT-III Complex HD Fly; Aggreg Yes
25 CHMP5 ESCRT-IV Complex Yes
26 VPS4A ESCRT-IV Complex Aggreg; Cell Tox
27 VPS4B ESCRT-IV Complex Aggreg
Aggreg, mammalian mHTT or C. elegans in vivo pure polyQ aggregation; HD Fly, Drosophila in vivo phenotypes platform; Cell Tox, Mammalian cell culture toxicity platform; MVBs,
multi-vesicular bodies.
TABLE 2 | Overlap of HD with exosome datasets.
Exosome Synaptic Exosome
Rel_892 ProteinDB_4019
n common FDR n common FDR
HTT Interactome_1619 295 2.1E-112 832 2.4E-228
PerturbDB_1218 203 1.5E-62 512 2.9E-92
HD Common_357 117 5.9E-70 222 2.7E-79
urine (Wang et al., 2012; Fraser et al., 2013), and as mRNA in
exosomes from cancer cells (Skog et al., 2008; Hong et al., 2009),
raising the interesting question as to whether mHTT might
also be detected in exosomes in HD patients. If true, then HD
joins the other neurodegenerative diseases where transmission
of misfolded pathogenic proteins between cells may play an
important role in disease pathology, and that the exosome
content in HD patients should be studied as potential biomarkers
for disease state and treatment status.
miRNA and their target genes have been implicated in
neuronal functions and in neurodegenerative diseases (Higa
et al., 2014). We curated two studies of differentially expressed
miRNAs in HD: in striatum of two mouse HD models (Lee et al.,
2011); and in humanHD patient brain frontal cortex and caudate
(Martí et al., 2010; Supplementary Datasheet 3) and found that
50–60% of differentially expressed miRNAs in HD are also found
in exosomes (Table 3). Other miRNAs linked to HD, such as
miR-22, a “perturbation” molecule due to its neuroprotective
properties in an HD cell culture platform (Jovicic et al., 2013),
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FIGURE 2 | Venn diagram of the intersections of the Exosome and HD
datasets. The area of the sets is approximately proportional to the set size,
with the number of genes indicated. The number following the underscore
indicates the total size of each dataset.
TABLE 3 | Overlap of miRNA in exosome (755) with miRNA changed in HD
brains.
miRNA changed n common % miRNA changed
Mouse R6/2_293 80 49 61
Mouse YAC128_169 79 52 66
Human HD Cortex 158 79 50
Human HD Caudate 131 66 50
and miR-214, miR-150, miR-146a, and miR-125b that target
the Htt gene (Sinha et al., 2011), are all found in exosomes.
Moreover, 7 of 11 miRNAs dysregulated in the frontal cortex of
HD monkeys are found in exosomes (Supplementary Datasheet
3), including the miRNA-128a that targets HTT and HIP1 and is
also downregulated in the brains of pre- and post-symptomatic
HD patients (Kocerha et al., 2014). Finally, miR-26 in astrocyte-
derived exosomes is involved in CNS diseases and synaptic
plasticity (Lafourcade et al., 2016), and is also differentially
expressed in HD. Conversely, neuronally released exosomes
can regulate expression of the glutamate transporter GLT1 in
astrocytes (Morel et al., 2013), and GLT1 is downregulated in
HD, leading to excess glutamate and deficient ascorbate in the
synapses that may contribute to HD (Miller et al., 2008, 2012;
Huang et al., 2010). The intriguing roles of exosomes in glial-
neuronal interaction and their potential involvement in HD
are further discussed in Supplementary Material Section 4 in
Supplementary Datasheet 4. Thus, both the proteins andmiRNAs
in exosomes are linked toHD and further support the importance
of exosome biology for HD.
Testing the Hypothesis that Exosome Dysfunction
Caused by mHTT Plays a Role in HD
In conclusion, the putative roles of HTT as a scaffolding protein,
its high intersection with synaptic proteins, its role in regulating
vesicular organelle movement, trafficking, and transport (Zala
et al., 2008, 2013; Roux et al., 2012; Liot et al., 2013; Fu and
Holzbaur, 2014), and it being part of the presynaptic cytomatrix
(Yao et al., 2014), are all possibly linked to various aspects of
exosome biology. The impact of mHTT could occur anywhere
along the life cycle of an exosome, from its biogenesis during
endosome formation and maturation, processing and transport
through theMVB, release from nerve terminals and other regions
of neurons and likely other cell types, and ultimately uptake
by postsynaptic neurons or by glia cells. The impact of mHTT
could also be cell and tissue specific, depending on the roles
of exosomes in those contexts. Many questions of exosome
synaptic biology are addressable in theDrosophilaNMJ platform,
and these will drive the critical experiments to translate and
validate in mammalian neuronal culture and other platforms,
where exosome biology is less well-studied. The abundance of
potential drug targets involved in exosome biology and the ability
of exosomes to carry disease biomarkers also provide a promising
path forward for HD drug discovery. A key question, however, is
which functions mediated by exosomes are impacted by mHTT
and contributes to disease.
Homeostatic Synaptic Plasticity in HD
Homeostatic Synaptic Plasticity is Implicated in
Multiple CNS Disorders
The critical role of exosome in a form of synaptic plasticity
at the Drosophila NMJ suggests a broader link to neuronal
plasticity, but this has been little studied. Whether and how the
impact of mHTT on synaptic activity drive disease pathology
is also unclear, as many studies HD models have reported
variable alterations in neuronal and synaptic activity in different
experimental platforms, although there is a focus on the
corticostriatal connections that are most vulnerable in HD
(reviewed in Raymond et al., 2011; Sepers and Raymond,
2014). The effects of mHTT, however, are likely countered by
compensatory mechanisms until clinical manifestation due to
the slow and progressive nature of HD. In this context, a key
synaptic regulatory mechanism, homeostatic synaptic plasticity
(HmSP), is particularly intriguing but has been little studied in
HD. Homeostasis is a fundamental feature of biological systems,
and HmSP is a form of “rheostat” control allowing the nervous
system to regulate repeated perturbations such as episodes of
synaptic plasticity within an optimal biological range (Lee et al.,
2014). Distinguishing features of HmSP include the multiple
levels it operates in, from synapses to cells to networks, the slow
time course of its induction and maintenance, and the likelihood
of a wide range of tolerated operational set points (some have
argued that “allostasis” is a more appropriate term and concept
Sterling, 2012). There are multiple forms of HmSP, including
synaptic downscaling and upscaling, in which chronic activation
or inhibition lead to compensatory decrease or increase
in postsynaptic responsiveness, respectively, often mediated
by availability of postsynaptic AMPA receptors (Turrigiano,
1999, 2007, 2012; Siddoway et al., 2014). Notably, mHTT
impacts AMPA receptor trafficking and impairs glutamatergic
neurotransmission (Mandal et al., 2011). Presynaptic HmSP is
mediated by compensatory changes in transmitter release due
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to chronic postsynaptic inhibition or activation, and involves
retrograde signaling and presynaptic transcriptional alterations
(Davis, 2013). Glia also regulate synaptic upscaling via TNF-
α signaling by altering the balance of synaptic AMPA and
GABA receptors (Pribiag and Stellwagen, 2013, 2014). HmSP
is drawing increasing interest as a fundamental mechanism
critical for neuronal functions, especially other forms of synaptic
plasticity. HmSP is particularly attractive as a neurodegeneration
mechanism because of its highly adaptable and context-
dependent nature operating over a long time frame. Thus, while
HmSPmay compensate for mHTT synaptic deficits (as suggested
in Rocher et al., 2016), dysfunctions in HmSP itself over timemay
also play pathogenic roles in HD.
A growing list of genes has been shown to play critical
roles in various forms of HmSP, and some are known to
also play key pathogenic roles in a number of CNS disorders.
For example, polyglutamine expansion in the Cav2.1 subunit
CACNA1A (OMIM ∗601011) of voltage-gated calcium channels
(VGCCs), the mammalian ortholog of the Drosophila gene
cacophony that is required for presynaptic HmSP (reviewed in
Frank, 2014), causes the autosomal dominant spinocerebellar
ataxia type 6 (SCA6, OMIM 183086), one of nine polyQ diseases
that include HD. Other mutations in this gene are associated with
Episodic ataxia, type 2 (OMIM 108500). Retrograde signaling
in HmSP engages transcription factors that include SMAD
and PAX members, and SMN1 (OMIM 600354), mutation
of which causes SMA, another monogenic neurodegenerative
disease. These transcriptional regulators at least partly modulate
expression of potassium channels of the Kv1 and Kv4 families
that together with VGCCs regulate the readily releasable pool of
transmitters (Lazarevic et al., 2013; Frank, 2014). Mutations in
KCNA1 (Kv1.1) cause Episodic Ataxia, Type 1 (OMIM 160120),
and those in KCND3 (Kv4.3) cause the very rare Spinocerebellar
Ataxia 19 (SCA19; OMIM 607346). Presynaptic HmSP signaling
also includes the BLOC-1 and SNARE complexes at the active
zone. Dysbindin (DTNBP1, OMIM 607145), a member of the
BLOC-1 complex, has been implicated in schizophrenia. Finally,
two genes required for postsynaptic HmSP are implicated in CNS
disorders, MECP2 (OMIM 300005) in Rett Syndrome and FMRI
(OMIM 309550; Chen et al., 2014) in the Fragile X Syndrome
and Fragile X-associated tremor/ataxia. MECP2 deficiency alters
HTT/HAP1 dependent axonal transport of BDNF and of APP
(Roux et al., 2012). Thus, mutations of genes all along the
pathway for HmSP lead to multiple CNS and neurodegenerative
disorders, supporting the importance of this mechanism for
normal functioning of the nervous system, and points to its
potential significance in HD.
Genes Required for HmSP and Their Protein
Networks Highly Overlap Both the HD and Exosome
Datasets
We curated the HmSP literature to produce a comprehensive
list of 143 genes that are critical for the proper functioning
of different forms of HmSP to perform enrichment analysis
(see Supplementary Datasheet 2). These 143 genes are highly
interconnected between themselves with only a handful
unconnected (queried in Ingenuity IPA, results not shown).
TABLE 4 | Overlap of HD datasets with HmSP Functional genes.
HmSP Functional Set_143
n common FDR % HD Set
HTT Interactome_1619 46 8.2E-18 3
PerturbDB_1218 49 2.4E-25 4
HD Common_357 24 9.6E-19 7
FIGURE 3 | Venn diagram of the 143 HmSP perturbation genes and
their distribution amongst the HD and Exosome datasets. The area of
the sets is approximately proportional to the set size, with the number of
genes indicated. The number following the underscore indicates the total size
of each dataset.
This HmSP Functional gene set highly intersects the HTT
Interactome and PerturbDB, with 71 genes or 50% found in
one or both of the HD datasets, and the relative % overlap
again higher in the HD Common set (Table 4). Many of the
49 PerturbDB genes overlapping the HmSP set are highly
connected nodal signaling genes (e.g., BDNF, mTOR, CAMKII,
AKT, CREB1) and are as well-known in the HD as they are in
neuronal functions and cell survival, suggesting HmSP as a novel
mechanism. Of the 143 HmSP genes, 72 or 50% are found in
the Exosome DB (which combines the Exosome Synaptic PPI
and Exosome ProteinDB), linking exosome biology to HmSP.
Of these 72 genes, 45 are found in either or both HD datasets.
Finally, 20 genes are common in HmSP, exosome, and HD
datasets. Ninety-eight of 143 HmSP genes are also found in the
HD and/or exosome datasets, with only 45 not present in these
datasets (Figure 3). This further suggests that exosome biology
and HmSP are each linked not only to HTT function and mHTT
pathogenesis but also to each other, and where they intersect
may be important for HD.
Continuing with our strategy of enrichment analysis of
protein networks built on key mechanistic genes, we curated
PPI sets for each of 65 known for their roles in mediating
eight specific forms of HmSP (Table S6 in Supplementary
Datasheet 4), then combining the PPI sets for each form of
HmSP: (1) presynaptic HmSP with Eph signaling to calcium
channels (VGCCs) and regulation of the readily releasable
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pools of transmitters; (2) retrograde signaling to presynaptic
neuron; (3) transcriptional regulation in presynaptic neurons; (4)
postsynaptic synaptic up-scaling and (5) down-scaling; (6) glial
TNFα-mediated up-scaling; (7) retinoic acid- and the Fragile X
gene FMR1mediated up-scaling; and finally (8) calcium signaling
via CAMKII and debrin for HmSP. The eight PPI sets show high
degree of intersection with each other, with 50% or more of genes
in each set in common with at least one other set (Table S7 in
Supplementary Datasheet 4), indicative of multiple overlapping
protein networks that are tightly controlled to coordinate the
critical neuronal modulatory functions of the specific forms
of HmSP. We then combined these eight sets into an HmSP
database (HmSP DB) of 3,782 unique genes, and the enrichment
analysis for this set is summarized here. The detailed analysis
is found in Supplementary Material Section 5 in Supplementary
Datasheet 4.
As expected, this larger representation of the HmSP functional
set shows highly significant overlap with the HD datasets, at
51% of the HTT Interactome and 48% of PerturbDB, and again
a higher 71% of HD Common (Table 5, Figure 4A). A similar
pattern of overlap with HD datasets holds true for the combined
Exosome DB and the 1,600 genes found in both HmSP and
the Exosome DBs. Again, the top two PerturbDB platforms that
overlap HmSP are the Drosophila in vivo phenotypes and mHTT
aggregation platforms (Table S8 in Supplementary Datasheet 4).
Conversely, for each of the HD datasets there is also an increase
in the relative % overlap of the HmSP-Exosome Common set vs.
the HmSP or Exosome DB alone (Figure 4B). A Venn diagram of
the HD datasets andHmSP and ExosomeDBs (Figure S5) further
supports their close tripartite relationships. A similar pattern
is observed for the PPI of each of the specific form of HmSP
and their common genes with the Exosome DB (Supplementary
Material Section 5, Tables S9A,B in Supplementary Datasheet 4).
Notably, there are a multitude of known drug targets in these
gene sets, many of which have been studied in the context of HD
but not with HmSP or exosome biology as endpoints, and others
that have not yet been implicated in HD. Notable are CDK5 and
calcium channels at the presynaptic level, PLK2 and others at the
postsynaptic dendrite, and β-catenin in both glial and synaptic
compartments, all highly connected in networks with multiple
druggable entry points that provide therapeutic opportunities
once the link to the disease is elucidated.
Testing the Hypothesis: Exosome is Involved in
HmSP, and Both are Dysfunctional in HD
The hypothesis that exosomes and HmSP are functionally linked
and collectively impacted by mHTT can be tested in the
well-characterized in vivo Drosophila andmammalian cell culture
platforms. Drosophila larval NMJ is best suited to test whether
presynaptic HmSP and exosome synaptic functions are linked,
then each mechanism and where they intersect can be tested
for the impact of expressing mHTT in motor neurons, glia or
perhaps even the postsynaptic muscle cells. When the mHTT
effects are characterized, then known HDmodifiers can be tested
for their impact on these endpoints. A concordance of modifiers
between the mHTT-driven exosome and HmSP endpoints in
the NMJ vs. behavioral phenotypes in the CNS would further
FIGURE 4 | Relative percent overlap of the HD datasets with the HmSP
and Exosome DB, and the converse. (A) Percentage of the HTT
Interactome, PerturbDB and HD Common (found in both sets) that overlap
with the HmSP DB, Exosome DB, and the HmSP-Exosome Common (found
in both DBs). (B) Percentage of the HmSP DB, Exosome DB, and the
HmSP-Exosome Common that overlap with each of the HD dataset is shown.
The number following the underscore indicates the size of each dataset.
TABLE 5 | Overlap of HD datasets with HmSP and exosome DBs.
HmSP DB_3782 Exosome DB_4469 HmSP-Exosome Common_1600
n common FDR n common FDR n common FDR
HTT Interactome_1619 825 5.6E-243 931 4.8E-270 586 1.3E-287
PerturbDB_1218 583 1.7E-151 593 9.2E-120 356 3.3E-132
HD Common_357 254 1.9E-117 265 1.8E-108 202 4.3E-139
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support the hypothesis. Postsynaptic HmSP such as upscaling
and downscaling are best studied in neuronal cell culture, and
experimental verification of the impact of mHTT on postsynaptic
HmSP is straightforward. Moreover, the role of exosomes in
postsynaptic HmSP will require further detailed study before
the question of mHTT’s impact can be addressed. Success will
lead to the development of new HD assays to test the effects
of genetic and pharmacological perturbations using these novel
mHTT readouts.
An important feature of HD that we have yet to address is
its inverse Q length dependency of the age-of-onset of motoric
symptoms. The vast majority of PerturbDB readouts are driven
by overexpressed mHTT generally of over 100 Qs. Lower Q
lengths of most clinical cases (>40 Q) do not induce robust
readouts. For example, HD patient fibroblasts with 49 and 70
Qs show a delay in receptor recycling to plasma membrane
via clathrin-coated vesicles because of aberrant Rab11 activity
(Li et al., 2009) and other downstream effects (Li et al., 2010,
2012), revealing a subtle deficiency in post-endocytic membrane
recycling in HD. Similarly, we predict that the impact of lower
Q length mHTT on exosome biology and HmSP are subtle and
difficult to detect unless additional stressors push the system
outside of its compensatory boundaries. We propose that HmSP
not only compensates for the effects of mHTT throughout life,
but that mHTT actually alters HmSP together with exosome
functions, so that eventually the dysfunction in homeostatic
mechanisms, perhaps in concert with aging, as the phenotypic
consequences of the HTT mutation become progressively more
apparent.
In conclusion, we hypothesize that exosomes are involved
in certain aspects of HmSP, similar to its critical role in fly
NMJ synaptic plasticity, and that WT HTT is involved in
both. This tripartite functional link is then altered by mHTT,
which eventually result in HD. Experimental verification of the
mHTT effects on exosome and HmSP functions in the NMJ
and neuronal cell culture platforms will enable further research
of both these mechanisms in HD and aid the hunt for drug
targets. This hypothesis does predict that WT HTT is involved in
exosome biology andHmSP, conceivably linked to themany roles
ascribed to HTT, such as transport and trafficking (Caviston and
Holzbaur, 2009), ER stress (Vidal et al., 2011), and transcription
(Moumné et al., 2013). Finally, our hypothesis may also be
relevant for the HTT lowering strategies currently in clinical
development that do not discriminate the WT from the mutant
form of HTT, as it is plausible that lowering both forms of HTT
too drastically may negatively impact the normal functioning of
exosome and HmSP and possibly confound any positive effects
due to the lowering of mHTT itself.
Protein Networks of Other
Neurodegenerative Disease Genes Overlap
the HD, Exosome, and HmSP Datasets
Curation of Protein Networks of Neurodegenerative
Disease Genes
We examined whether protein networks of pathogenic genes for
neurodegenerative diseases that share with HD the slow onset,
progressive deterioration, and regional selectivity of pathologies
are also linked to HmSP and exosome biology, particularly
as many HmSP genes are already implicated in multiple CNS
disorders. Several pathogenic PD genes are also part of the HD
PerturbDB: SNCA (α-synuclein; Furlong et al., 2000; Corrochano
et al., 2011), PARK2 (parkin; Rubio et al., 2009), and PARK7
(DJ-1; Sajjad et al., 2014), and more recently, but not yet
curated into PerturbDB, PINK1 (Khalil et al., 2015). Thus,
perturbation of these genes in their WT form can alter mHTT-
driven outcomes, indicative of a close biological relationship
between their functions and mHTT pathophysiology. To extend
to other neurodegenerative diseases, we first curated well-
known pathogenic genes for PD, AD, eight PolyQ diseases
but excluding HD, ALS, and SMA into the Neurodegenerative
Disease (NeuroD) PPI gene sets, as described in Methods Section
Gene Sets and shown in Table 6. These range from the smallest
set of 51 genes in the ATXN2 set (for SCA2) to the largest of
2,133 genes for APP (AD), with most others in the low hundreds
of genes. We also combined each PPI into its cognate NeuroD to
form larger disease specific gene sets for enrichment analyses. All
the gene lists are in Supplementary Datasheet 2.
The NeuroD Protein Networks Highly Overlap the HD
Datasets and Each Other
We first examined the overlap of each NeuroD PPI with the
HTT Interactome, as they are all protein networks centered
on pathogenic disease genes. Interestingly, there is significant
overlap, particularly for the PD PPIs, with 59% of SNCA (α-
synuclein) at the highest (−log FDR ∼165) and 44% of PARK2
at the lowest (−log FDR ∼40). While these genes only account
for portion of PD cases, their role in protein folding, misfolded
protein processing and mitochondrial functions suggests these
mechanisms are important for both diseases. The microtubule-
associated tau (MAPT) PPI also highly overlaps the HTT
Interactome, at 57% with −log FDR ∼44. The role of tau, in
its multiple isoforms and phosphorylation states for cytoskeletal
functions, has just recently been implicated in HD (Fernández-
Nogales et al., 2014; Blum et al., 2015; Gratuze et al., 2015; Vuono
et al., 2015). Some of the PolyQ disease genes, especially the
VGCC subunit in SCA6 at 40% (−log FDR ∼40), points to the
importance of calcium dysregulation in HD (Giacomello et al.,
2013). We then combined the PPI sets into their respective five
disease sets (Table 7, Figure 5), finding again the highest overlap
of the HTT Interactome with the PD set (48%,−log FDR∼224).
Moreover, the NeuroD PPIs overlap PerturbDB with the HD
Common set again showing higher % overlap than each HD
dataset (Table 7, Figure 5; SMA at 4% each for the HD single sets
and 6% forHDCommon). As is the case for other datasets, within
PerturbDB the Drosophila in vivo and mammalian aggregation
platforms again most highly overlap the NeuroD PPI sets (Tables
S10A,B in Supplementary Datasheet 4). Thus, the overlapping
NeuroD protein networks contain many modifiers of mHTT-
driven outcome measures, and perhaps many are also modifiers
for other neurodegenerative diseases. Finally, the NeuroD PPI
sets also significantly overlap each other, with about 72% of the
PD and ALS sets intersecting at least one other NeuroD set
(Table S11 in Supplementary Datasheet 4; Figure S6). Indeed,
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TABLE 6 | Overlap of NeuroD PPI sets with HTT interactome_1619.
Gene ID Symbol|Disease n PPI n common HTT PPI FDR % Set NeuroD
PD Set 763 370 5.4E-224 48
6622 SNCA 398 235 9.7E-165 59
120892 LRRK2 198 108 3.2E-69 55
11315 PARK7 147 73 6.0E-43 50
5071 PARK2 176 77 2.7E-40 44
65018 PINK1 52 25 1.2E-14 48
AD Set 2354 400 1.1E-65 17
4137 MAPT 118 67 2.2E-44 57
5663|5664 PSEN1|2 253 97 1.2E-44 38
351 APP 2133 310 3.3E-35 15
PolyQ Set 1139 303 2.1E-96 27
773 CACNA1A|SCA6 215 87 3.1E-42 40
4287 ATXN3|SCA3 98 44 1.0E-23 45
6311 ATXN2|SCA2 51 21 7.6E-11 41
6310 ATXN1|SCA1 272 74 2.7E-23 27
367 AR|SBMA 325 86 4.3E-26 26
6908 TBP|SCA17 246 57 1.0E-14 23
6314 ATXN7|SCA7 87 23 1.5E-07 26
1822 ATN1|DRPLA 115 28 3.7E-08 24
ALS Set 328 123 1.7E-55 38
6647 SOD1 84 36 1.0E-18 43
23435 TARDBP 120 46 2.5E-21 38
2521 FUS 159 54 5.0E-22 34
SMA 6606|6607 SMN1|2 241 67 1.10E-21 28
TABLE 7 | Enrichment analysis of HD and NeuroD PPI datasets.
HTT Interactome_1619 PerturbDB_1218 HD Common_357
n common FDR n common FDR n common FDR
PD_PPI_763 370 5.4E-224 232 2.5E-111 150 5.8E-124
PolyQ_PPI_1139 303 2.1E-96 220 3.2E-64 113 3.0E-57
AD_PPI_2354 400 1.1E-65 280 4.2E-38 127 6.2E-36
ALS_PPI_328 123 1.7E-55 80 1.2E-29 47 1.5E-29
SMA_PPI_241 67 1.1E-21 48 2.4E-14 23 7.7E-11
the subsets of each NeuroD PPI found in common with the
HTT Interactome are even more highly overlap with each other
(Figure S7), suggesting an even tighter interlocking protein
network for neurodegenerative pathogenic genes centered on
HTT that when perturbed at different points can contribute to
pathogenesis in distinct diseases. More detailed analysis of the
NeuroD PPIs is presented in Supplementary Material Section 6.1
in Supplementary Datasheet 4.
The NeuroD Protein Networks Highly Intersect the
Exosome and HmSP Datasets
Not surprisingly, the NeuroD PPIs also highly overlap the
Exosome and HmSP DBs (Table 8), with % overlap ranging from
mid 30s for AD to 60s for PD and ALS, and −log FDR values
generally in the hundreds. The intersection with the HmSP and
ExosomeDBs is higher for NeuroD PPIs that are in commonwith
the HTT Interactome (+HTT) than those that do not (−HTT),
as exemplified for PD (75% and 52% respectively, Figure 6). The
same pattern holds true for the Exosome DB and the HmSP-
Exosome Common set (Figure 6), most with −log FDR values
over 100 (Table S12 in Supplementary Datasheet 4). The same
pattern of increased relative % overlap is true and perhaps even
more striking for the remaining NeuroD sets, as shown in Figure
S8 (the SMA set increases from 48 to 73%; data not shown). These
results suggest that there aremore biological links betweenHmSP
and exosomes and the NeuroD protein networks that overlap
with the HTT Interactome compared to the parts of the network
that do not.
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Finally, the overlap of the NeuroD sets is higher for genes in
theHmSP-ExosomeCommon set vs. those in eachDB alone, with
the exception of the PolyQ (Figure S9). This again supports a
linkage between HmSP and exosome biology, and furthermore
that where the two mechanisms intersect is particularly
important for the pathophysiology of these neurodegenerative
diseases. Again, when the NeuroD PPIs are segregated into
the subsets that overlap the HTT Interactome, the relative
% overlap is even higher (Figures S9A,B in Supplementary
Datasheet 4). This is particularly prominent for the PolyQ PPIs,
where the increased relative % overlap is obvious only for the
+HTT subset. The same trend is found for the constituent
subsets of HmSP (e.g., presynaptic, up-scaling and down-
scaling etc.) as presented in Tables S13A–F in Supplementary
Datasheet 4. Thus, as in the case for HD, there appears to
be strong linkages between exosome biology and HmSP, and
particularly where the two mechanisms intersect, with the other
neurodegenerative diseases. As discussed for HD, experimental
verification of the hypothesis is needed, using experimental
platforms driven by the appropriate mutant NeuroD pathogenic
genes, to determine if exosome and HmSP functions are indeed
altered.
FIGURE 5 | Relative percent overlap of the HD datasets with the
NeuroD PPI sets. Percentage of the HTT Interactome, PerturbDB and HD
Common (found in both sets) that overlap with PD, PolyQ, AD, and ALS PPI
sets is shown. The number following the underscore indicates the size of each
dataset.
Transcripts Localized to Synapses Highly
Overlap the HD and NeuroD Datasets
mHTT has long been known to affect transcription of a variety
of genes, and this is postulated as a primary pathology drivers
(Moumné et al., 2013). We found that a set of differentially
expressed genes in postmortem HD patient caudate and motor
cortex (Kuhn et al., 2007) highly overlaps the HTT Interactome
and PerturbDB (unpublished results), and we plan to integrate
the results presented here with new analyses of a comprehensive
set of HD transcriptomic studies (Langfelder et al., 2016).
Synaptic plasticity, including HmSP, ultimately involves complex
transcriptional alterations over the longer term, and exosomes
can carrymiRNA to alter transcription in the receiving cells. HTT
itself has also been postulated to be involved in trafficking of
RNA granules, interacts with Ago2, and contributes to localized
transcription changes at the synapses (Culver et al., 2012).
Thus, synaptic control of local translation in the synapses to
support synaptic function and their potential to contribute
to pathogenesis deserves further investigation (Thomas et al.,
2014). In the meantime, we have incorporated a large set
of transcripts identified by deep sequencing of microdissected
synaptic neuropil regions from hippocampal CA1 that are
FIGURE 6 | Relative percent overlap of the PD PPI with the HmSP and
Exosome DBs. Percent of the PD PPI sets that intersect the HmSP DB,
Exosome DB, and the genes found in both HmSP and Exosome DBs
(HmSP-Exosome) are shown. The PD PPI sets are the entire set (PD Total), the
subset found in common with the HTT Interactome (PD +HTT), or the subset
with no overlap with HTT Interactome (PD no HTT). The number following the
underscore indicates the size of each dataset.
TABLE 8 | Overlap of NeuroD PPIs with HmSP and exosome DBs.
HmSP DB_3782 Exosomes DB_4469 HmSP Exosome Common_1600
n common FDR % Set n common FDR % Set n common FDR % Set
PD PPI_763 480 4.9E-187 63 494 2.7E-167 65 354 1.2E-206 46
PolyQ PPI_1139 736 1.4E-306 65 440 6.3E-51 39 349 2.5E-134 31
AD PPI_2354 861 4.2E-135 37 824 6.4E-75 35 473 1.8E-108 20
ALS PPI_328 229 1.1E-100 70 203 1.3E-61 62 162 8.5E-96 49
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TABLE 9 | Overlap of synaptic localized transcript with HD and NeuroD
datasets.
Synaptic Localized Transcripts_2305
HD Sets n common FDR % Set NeuroD
HTT Interactomes_1619 436 1.31E-87 27
PerturbDB Total_1218 282 1.98E-40 23
HD Common_357 113 1.55E-27 31
NeuroD SETS
PD All PPI_763 177 2.13E-25 23
PD +HTT PPI_371 111 3.49E-25 30
PolyQ All PPI_1139 223 1.99E-21 20
PolyQ +HTT PPI_303 86 7.79E-18 28
AD All PPI_2354 404 7.92E-27 17
AD +HTT PPI_400 119 1.39E-26 30
ALS All PPI_328 88 2.13E-16 27
ALS +HTT PPI_123 44 6.85E-13 36
putatively localized to synapses (Cajigas et al., 2012) and
may therefore mediate local transcription in response to rapid
synaptic alterations. This set of 2,305 transcripts contains a large
fraction of synaptic proteins that include signaling molecules and
scaffolds. This local synaptic transcriptome significantly overlaps
the HTT Interactome, PerturbDB andNeuroD PPI sets (Table 9).
A detailed table of the overlap for the HD subsets is shown in
Table S13 and discussed in Supplementary Material Section 7 in
Supplementary Datasheet 4. An increase in the relative % overlap
with each NeuroD subset that is found in common with the HTT
Interactome is again observed (Table 9). Moreover, this Synaptic
Localized Transcript set also overlaps the HmSP and Exosome
DBs at 32 and 33%, respectively, suggesting the involvement of
locally regulated transport and transcription of mRNA. Indeed,
the Synaptic Localized Transcript genes that overlap with either
HmSP or Exosome DBs show higher relative % overlap with the
HD datasets and with the NeuroD PPI sets compared to the
whole Synaptic Localized Transcript set (Figure S10). Finally, the
subset found in common in the Synaptic Localized Transcripts,
HmSP, and Exosome DBs shows the highest overlap for HD
and all NeuroD datasets. These results suggest that these local
transcripts may play a role in all both mechanisms, and likewise
may be involved in HD and other neurodegenerative disease
pathophysiology.
What Are the Therapeutic Opportunities?
Querying for terms such as “kinase” under GO in Supplementary
Datasheet 2 shows that Exosome and HmSP DBs are full of
known drug targets. While evaluation of these drug targets
as therapeutic opportunities for neurodegenerative diseases
requires first the validation of exosome and HmSP functions
in HD and development of therapeutic rationale, some of the
drug targets are nevertheless interesting to consider because of
their established links to HD, albeit under different mechanistic
contexts such as cell toxicity. Prominent examples are calcium
dysregulation with targets such as VGCCs that are important
for presynaptic HmSP, PLK2 that opposes the action of NFκB
signaling pathway at the dendritic spines to regulate homeostatic
end point for excitatory synaptic adaptation (Mihalas et al., 2013),
and the interaction between PLK2 andCDK5,mTOR, and EphA4
to regulate HmSP. Sharp pharmacological tool compounds are
available for many of these targets and can be used to elucidate
their roles in the disease context. Indeed, if particular functional
parts of HmSP and exosomes are altered in different disease
contexts to give rise to the corresponding clinical features, then
an exciting possibility is that such imbalance in HmSP could be
restored by pharmacological perturbation of the critical signaling
molecules. Given that HmSP is by definition context-dependent,
it may well be that drugs that impact HmSP function could
be useful in multiple indications. The first order of business,
however, is to simply determine if any of the multiple form
of HmSP and exosome functions are altered by the NeuroD
pathogenic genes, as has already been shown for SMN for SMA
and the calcium channel subunit CACNA1A for SCA6. If the
answer is yes, and depending on what the alterations are for
each pathogenic genes, a promising avenue of new drug discovery
programs will open up for the neurodegenerative diseases. A
preliminary, generalized flow scheme for such a drug discovery
program is shown in Figure S11. A key recommendation is the
cross-fertilization between mechanistic experimental platforms,
leveraging the advantages of the in vivo context of the Drosophila
platform and the utility of mechanistically specified cell culture
platform into new drug discovery assays. Moreover, exosomes
may provide disease biomarkers from patients. Most interesting
is that given the extensive overlap between the two mechanisms
and the protein networks of multiple neurodegenerative diseases,
findings for each of the diseases may be relevant for the others.
CONCLUSIONS
We have developed a database-enabled systems biological
methodology to systematically organize, curate, and analyze large
sets of HD data and link them with their gene IDs to the
published literature based on the co-cited gene IDs and MeSH
terms in each PubMed article. This allows for efficient manual
scanning of the literature for mechanisms of interest based on
co-citation of genes of interest from datasets and MeSH terms
of interest. The identification of mechanisms in the datasets then
leads to building of mechanistic gene sets for enrichment analyses
and rank ordering. We deployed this methodology to uncover
novel biological mechanisms of exosomes and homeostatic
synaptic plasticity that are both implicated in the normal function
of HTT and the pathology of mHTT. These two mechanisms are
also linked to protein-protein networks centered on pathogenic
genes for PD, AD, ALS, SMA, and other polyQ diseases.
Moreover, all these protein networks, including that of HTT, also
highly intersect each other, indicating that they may all engage
exosome biology andHmSP at distinct points that may ultimately
contribute to the different disease pathologies. These hypotheses
can be verified by straightforward experiments in the appropriate
platforms. If confirmed, there will be multiple potential drug
targets that can be evaluated as therapeutic opportunities, and
novel screening assays and biomarkers will also be developed
and tested as tools for therapeutic development for multiple
neurodegenerative diseases.
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